About Open Access
Supply chain management in regenerative medicine manufacturing
Lookup NU author(s)
Dr Lucy Foley
Professor Christian Hicks
Hicks C; Foley LA; O'Neill P
Spath, D., Ilg, R., Krause, T.
Conference Proceedings (inc. Abstract)
21st International Conference on Production Research: Innovations in Product and Production
Year of Conference
31 July - 4 August 2011
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Cell therapies may cure chronic disease, but the use of living cells as therapies raises many supply chain challenges, which are explored in this paper. There are two types of cell therapy. Allogeneic therapies are where a single donor treats many patients. Autologous therapies are where the patient supplies their own cells, which are expanded and implanted back into the patient. Most cell therapies are still manufactured in a research environment. Industrializing allogeneic treatments means scaling up production. Perhaps more challenging, autologous treatments need to be scaled out and require a service model. Lead times and quality are key which requires supply chains need to be Lean and agile. The design of supply chains for cell therapies involves establishing strategic, operational and contractual relationships; developing coordinated, robust, lean and agile processes; maintaining quality with traceability; together with fast and reliable logistics.
Fraunhofer IRB Verlag
Search Newcastle University Library for this item
Newcastle University Library, NE2 4HQ, United Kingdom. Tel: 0044 (191) 222 7657
©2016 Newcastle University Library